6 Dimensions Capital led a round for the miniprotein drug developer, founded by Harvard researcher Gregory Verdine.
FogPharma, a US-based miniprotein developer based on research at Harvard University, closed a $66m series B round on Wednesday led by 6 Dimensions Capital.
6 Dimensions Capital, the fund formed by pharmaceutical firm WuXi AppTec and VC firm Frontline BioVentures, was joined by property developer Nan Fung Group, conglomerate Alphabet’s GV unit and WuXi AppTec’s WuXi AppTec Corporate Ventures subsidiary.
Blue Pool Capital, Horizons Ventures, Leerink Partners, Deerfield Management, Boyu Capital and unnamed non-institutional investors also contributed funding.
Founded in 2015, FogPharma is developing miniprotein treatments for cancer that are intended to mix the targeting power of biologics with small molecules’ ability to penetrate cells.
The company was founded by Gregory Verdine, the Erving professor of chemistry in the departments of Stem Cell and Regenerative Biology, Chemistry and Chemical Biology and Molecular and Cellular Biology at Harvard Universtiy.
The series B capital will drive the progress of the company’s lead program, an inhibitor of the beta-catenin protein, into phase 2 development for cancer indications. It plans to advance the candidate into the clinic by the end of 2019.
Krishna Yeshwant, a general partner at GV, will join FogPharma’s board of directors in connection with the latest round, along with 6 Dimensions CEO Leon Chen and entrepreneur Rick Klausner.
The series B followed $11m in seed and series A funding, according to FogPharma, which identified WuXi AppTec Corporate Ventures, Deerfield Management and Boyu Capital as existing investors.
– A version of this article first appeared on our sister site, Global Corporate Venturing.
